Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
Management of Insomnia01:19

Management of Insomnia

The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Annotated digital image correlation displacement fields from fatigue crack growth experiments on aluminium alloys.

Scientific data·2026
Same author

Aprocitentan: A New Option for Resistant Hypertension and Its Place in Patient Care.

Southern medical journal·2026
Same author

Shared visits vs incident-to billing for pharmacy services.

Journal of managed care & specialty pharmacy·2026
Same author

Paediatric Adenoidectomy: A Retrospective Cohort Study of Clinical Practice and Outcomes in NHS England (2008-2024).

Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery·2026
Same author

Predicting Continental-Scale Soil Mercury Concentrations in Australia to Refine Global Frameworks.

Environmental science & technology·2026
Same author

Enhancing adherence to guideline-directed use of anticoagulant therapy in atrial fibrillation: a triad of quality improvement interventions in an academic outpatient setting.

BMJ open quality·2026
Same journal

Obesity-Related Insulin Resistance Indices and CKD Risk in Patients with Diabetes and Coronary Heart Disease: A Multicenter Cohort Analysis.

Diabetes, metabolic syndrome and obesity : targets and therapy·2026
Same journal

Targeting Mitochondria-Associated Endoplasmic Reticulum Membranes (MAMs): A Novel Therapeutic Strategy for Diabetic Complications.

Diabetes, metabolic syndrome and obesity : targets and therapy·2026
Same journal

Association Between First-Trimester Gestational Weight Gain and the Risks of Gestational Diabetes Mellitus and Macrosomia.

Diabetes, metabolic syndrome and obesity : targets and therapy·2026
Same journal

Integrated Bioinformatic and Experimental Identification of DHCR24 and NRG1 as Key Cellular Aging Genes in Diabetic Cardiomyopathy.

Diabetes, metabolic syndrome and obesity : targets and therapy·2026
Same journal

Inflammation Mediates the Relationship Between Serum Uric Acid and New-Onset Diabetes Risk in Patients with Coronary Heart Disease: Results from a Multicenter Cohort Study.

Diabetes, metabolic syndrome and obesity : targets and therapy·2026
Same journal

Mediating Role of Plasma Biomarkers Associated with Metabolic Syndrome in Cognitive Decline Among Older Adults.

Diabetes, metabolic syndrome and obesity : targets and therapy·2026
See all related articles

Related Experiment Video

Updated: May 10, 2026

Multidisciplinary Approach to Obesity Management: A Case Report
05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

Lorcaserin for weight management.

James R Taylor1, Eric Dietrich, Jason Powell

  • 1University of Florida College of Pharmacy, Department of Pharmacotherapy and Translational Research, Gainesville, FL, USA.

Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy
|June 22, 2013
PubMed
Summary
This summary is machine-generated.

Lorcaserin effectively aids weight loss in obese patients with type 2 diabetes, reducing body mass and improving health markers. This medication targets serotonin receptors to decrease appetite and increase fullness.

Keywords:
diabeteslorcaserinobesity

More Related Videos

An Acupoint Catgut-embedding Therapy for Treating Obesity
04:50

An Acupoint Catgut-embedding Therapy for Treating Obesity

Published on: April 4, 2025

Related Experiment Videos

Last Updated: May 10, 2026

Multidisciplinary Approach to Obesity Management: A Case Report
05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

An Acupoint Catgut-embedding Therapy for Treating Obesity
04:50

An Acupoint Catgut-embedding Therapy for Treating Obesity

Published on: April 4, 2025

Area of Science:

  • Pharmacology
  • Endocrinology
  • Obesity Medicine

Background:

  • Obesity and type 2 diabetes frequently coexist, with obesity driving insulin resistance.
  • Weight loss interventions are crucial for managing type 2 diabetes and reducing cardiovascular risk.
  • Pharmacological agents offer an additional strategy for weight management in obese individuals.

Purpose of the Study:

  • To review clinical trials of lorcaserin for weight loss in obese patients.
  • To evaluate the efficacy and safety of lorcaserin, particularly in patients with type 2 diabetes.
  • To explore the patient perspective and potential role of lorcaserin in obesity management.

Main Methods:

  • Review of clinical trials investigating lorcaserin's effects on weight loss and metabolic parameters.
  • Analysis of adverse events and safety profiles associated with lorcaserin use.
  • Assessment of lorcaserin's impact on obese patients with and without type 2 diabetes.

Main Results:

  • Lorcaserin demonstrated an average weight loss of approximately 5.5 kg over one year in obese patients with type 2 diabetes.
  • Common side effects included headache, back pain, nasopharyngitis, and nausea.
  • Increased incidence of hypoglycemia was observed in lorcaserin groups, though episodes were not severe.

Conclusions:

  • Lorcaserin is an effective weight-loss medication for obese individuals, including those with type 2 diabetes.
  • The drug is approved for use in specific patient populations alongside diet and exercise.
  • Further research is needed to clarify lorcaserin's definitive role in comprehensive obesity treatment.